Dermata Therapeutics Inc (NASDAQ: DRMA) is a dermatology company that pivoted in September 2025 from prescription drug development to commercializing over-the-counter skincare products under the Tome brand. The company has not yet generated commercial product revenue as of the 10-K filed March 26, 2026, and is pre-revenue, funded through equity and debt financings. Tome is planned for a mid-2026 launch via a dual-channel strategy combining direct-to-consumer digital marketing and business-to-business sales targeting skincare professionals through a Tome certification program. The company has a history of net losses and has never launched a commercial product. It operates in the highly competitive OTC skincare market, where products are regulated under FDA OTC monograph requirements. Fulfillment is planned through third-party warehousing and shipping partners. Retention mechanics include subscription or auto-replenishment, loyalty programs, and lifecycle email and SMS marketing.

Revenue model

No revenue has been generated as of the filing date. The planned model is transactional DTC product sales and B2B sales to skincare professionals, with subscription and auto-replenishment offerings intended to drive repeat purchases. The company has funded operations through public and private equity financings, including an ATM agreement with H.C. Wainwright and Co. LLC dated June 7, 2024.

Products and services

Tome skincare line, anchored by a product called Foundational Treatment, which features a once-weekly application routine. The line is positioned around a proprietary 'multidimensional hero ingredient.' A Tome certification program is planned to credential skincare professionals. No commercial product had been launched as of the 10-K filed March 26, 2026.

Customers and end markets

Two target segments: direct consumers seeking at-home skincare solutions, and skincare professionals (estheticians and in-office practitioners) addressed through the B2B channel and Tome certification program. End market is OTC consumer skincare.

Value-chain role

Product developer and brand owner at the formulation and commercialization stage. Manufacturing and supply sourced externally, including a supply agreement with Reka-Farm LLC dated February 27, 2020. Fulfillment handled through third-party warehousing and shipping partners. No proprietary retail or manufacturing infrastructure disclosed.

Geographic exposure

United States. No international operations disclosed in the filing excerpts.

Source: SEC 10-K, filed 2026-03-26

Industry: Pharmaceutical Preparations Peers: Avenue Therapeutics Inc Evoke Pharma Inc Grapefruit USA, Inc Johnson & Johnson Stablecoin Development Corp Senestech Inc Stem Holdings, Inc.